Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)

被引：144

作者：

Davidson, RN

diMartino, L

Gradoni, L

Giacchino, R

Gaeta, GB

Pempinello, R

Scotti, S

Cascio, A

Castagnola, E

Maisto, A

Gramiccia, M

diCaprio, D

Wilkinson, RJ

Bryceson, ADM

机构：

[1] UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,LONDON,ENGLAND

[2] HOSP TROP DIS,LONDON NW1 0PE,ENGLAND

[3] UNIV NAPLES FEDERICO II,NAPLES,ITALY

[4] UNIV NAPLES 2,OSPED D COTUGNO,DIV PEDIAT 1,NAPLES,ITALY

[5] IST GIANNINA GASLINI,I-16148 GENOA,ITALY

[6] OSPED BAMBINI BRESCIA,PALERMO,ITALY

[7] OPSED CASERTA,CASERTA,ITALY

[8] IST SUPER SANITA,I-00161 ROME,ITALY

来源：

CLINICAL INFECTIOUS DISEASES | 1996年 / 22卷 / 06期

关键词：

D O I：

10.1093/clinids/22.6.938

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12 mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommend a total dose of AmBisome of greater than or equal to 20 mg/kg, given in greater than or equal to 5 doses of 3-4 mg/kg over greater than or equal to 10 days.

引用

页码：938 / 943

页数：6

共 22 条

[1] RELAPSE OF VISCERAL LEISHMANIASIS IN PATIENTS WHO WERE COINFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS AND WHO RECEIVED TREATMENT WITH LIPOSOMAL AMPHOTERICIN-B [J].